A GD2 and GD3 ganglioside conjugate vaccine

Where it participates (unsigned role)

1. Eligible patients receiving GD2/GD3 vaccine were randomly assigned to group 1 with 54 patients to receive no beta-glucan or group 2 with 53 patients to receive an oral beta-glucan regimen during the first 5 weeks of vaccine priming, and from week 6 onwards all 107 patients received oral beta-glucan during vaccine boost, adding oral beta-glucan during the first 5 weeks of vaccine priming elicited a higher anti-GD2 IgG1 antibody response in group 2 at 1.80 with 90% CI 0.12 to 3.39 and P = .08 against a planned type I error of 0.10, antibody titre correlated significantly with dectin-1 single nucleotide polymorphism, and the genotype frequency, seroconversion rates and vaccine-related toxic effects were similar in the 2 groups.

   Yeast beta-(1->3)/(1->6)-glucan → Anti-GD2 IgG1 antibody titre source_derived_draftungraded
   Experimental context and source evidence

   evidence_span

   {"source_cache": "artifacts/glucan-research/36547975.abstract.txt", "locator": "Indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "156766d12dba66e36fba78a5ca31f9c41f50f88f74817ba4d545a7a3ed5e23f2", "start_char": 0, "end_char": 2766, "text_sha256": "156766d12dba66e36fba78a5ca31f9c41f50f88f74817ba4d545a7a3ed5e23f2"}

   experimental_model

   Phase 2 randomised clinical trial isolating the adjuvant effect during the vaccine priming phase

   exposure

   Oral beta-glucan during the first 5 weeks of GD2/GD3 vaccine priming against none, with all patients receiving glucan from week 6 onward

   limitations

   A randomised design that isolates one adjuvant window, with a prespecified type I error of 0.10 rather than the conventional 0.05. The endpoint is an antibody titre, not survival.

   nutrient_topic

   Beta-glucan research collection; topical membership is not evidence of a direct clinical effect, and each preparation is recorded as its own entity with no family link joining any pair. · Beta-glucan

   organism

   Human

   plain_language

   Starting the glucan earlier raised the antibody the vaccine was meant to raise, at a significance bar the trial had set in advance at one in ten.

   primary_references

   [bg-p36547975] Effect of Oral β-Glucan on Antibody Response to Ganglioside Vaccine in Patients With High-Risk Neuroblastoma: A Phase 2 Randomized Clinical Trial. (2023). https://pubmed.ncbi.nlm.nih.gov/36547975/ DOI: 10.1001/jamaoncol.2022.5999

   tissue_or_cell_type

   High-risk neuroblastoma

   Beta-glucan: a structural family rather than an agent, what decides whether a bound glucan actually signals, the complement route that a cereal and a yeast preparation share, and the unequal human evidence behind each (2026-09-22) · lines 359–370

   AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Phase 2 randomised clinical trial isolating the adjuvant effect during the vaccine priming phase · source_derived_draft · unverified_draft

   ### bg-immunogenicity-in-genetic-responders Eligible patients receiving GD2/GD3 vaccine were randomly assigned to group 1 with 54 patients to receive no beta-glucan or group 2 with 53 patients to receive an oral beta-glucan regimen during the first 5 weeks of vaccine priming, and from week 6 onwards all 107 patients received oral beta-glucan during vaccine boost, adding oral beta-glucan during the first 5 weeks of vaccine priming elicited a higher anti-GD2 IgG1 antibody response in group 2 at 1.80 with 90% CI 0.12 to 3.39 and P = .08 against a planned type I error of 0.10, antibody titre correlated significantly with dectin-1 single nucleotide polymorphism, and the genotype frequency, seroconversion rates and vaccine-related toxic effects were similar in the 2 groups. Condition category: normal nutrient_topic: Beta-glucan research collection; topical membership is not evidence of a direct clinical effect, and each preparation is recorded as its own entity with no family link joining any pair. plain_language: Starting the glucan earlier raised the antibody the vaccine was meant to raise, at a significance bar the trial had set in advance at one in ten. organism: Human tissue_or_cell_type: High-risk neuroblastoma experimental_model: Phase 2 randomised clinical trial isolating the adjuvant effect during the vaccine priming phase limitations: A randomised design that isolates one adjuvant window, with a prespecified type I error of 0.10 rather than the conventional 0.05. The endpoint is an antibody titre, not survival. exposure: Oral beta-glucan during the first 5 weeks of GD2/GD3 vaccine priming against none, with all patients receiving glucan from week 6 onward evidence_span: {"source_cache": "artifacts/glucan-research/36547975.abstract.txt", "locator": "Indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "156766d12dba66e36fba78a5ca31f9c41f50f88f74817ba4d545a7a3ed5e23f2", "start_char": 0, "end_char": 2766, "text_sha256": "156766d12dba66e36fba78a5ca31f9c41f50f88f74817ba4d545a7a3ed5e23f2"} [bg-p36547975] Effect of Oral β-Glucan on Antibody Response to Ganglioside Vaccine in Patients With High-Risk Neuroblastoma: A Phase 2 Randomized Clinical Trial. (2023). https://pubmed.ncbi.nlm.nih.gov/36547975/ DOI: 10.1001/jamaoncol.2022.5999

   Complete structured claim and evidence